Exelixis

NASDAQ
EXEL
Promoção
Lucratividade por seis meses: +9.78%
Rendimento de dividendos: 0%
Setor: Healthcare
Notícias
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?

15 julho 13:50 Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

2 julho 12:34 Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch

24 junho 16:15 EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch